Portal de Periódicos da CAPES

Glycosaminoglycan Modifications in Duchenne Muscular Dystrophy

2014; Oxford University Press; Volume: 73; Issue: 8 Linguagem: Inglês

10.1097/nen.0000000000000098

1554-6578

Elisa Négroni, Emilie Hénault, Fabien Chevalier, Marie Gilbert-Sirieix, Toin H. Van Kuppevelt, Dulce Papy‐Garcia, Georges Uzan, Patricia Albanese,

Electrospun Nanofibers in Biomedical Applications

Widespread skeletal muscle degeneration and impaired regeneration lead to progressive muscle weakness and premature death in patients with Duchenne muscular dystrophy (DMD). Dystrophic muscles are progressively replaced by nonfunctional tissue because of exhaustion of muscle precursor cells and excessive accumulation of extracellular matrix (ECM). Sulfated glycosaminoglycans (GAGs) are components of the ECM and are increasingly implicated in the regulation of biologic processes, but their possible role in the progression of DMD pathology is not understood. In the present study, we performed immunohistochemical and biochemical analyses of endogenous GAGs in skeletal muscle biopsies of 10 DMD patients and 11 healthy individuals (controls). Immunostaining targeted to specific GAG species showed greater deposition of chondroitin sulfate (CS)/dermatan (DS) sulfate in DMD patient biopsies versus control biopsies. The selective accumulation of CS/DS in DMD biopsies was confirmed by biochemical quantification assay. In addition, high-performance liquid chromatography analysis demonstrated a modification of the sulfation pattern of CS/DS disaccharide units in DMD muscles. In conclusion, our data open up a new path of investigation and suggest that GAGs could represent a new and original therapeutic target for improving the success of gene or cell therapy for the treatment of muscular dystrophies.